USA flag logo/image

An Official Website of the United States Government

A novel compound to selectively protect normal tissues from chemotherapy

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
95855
Program Year/Program:
2010 / SBIR
Agency Tracking Number:
CA137933
Solicitation Year:
N/A
Solicitation Topic Code:
NCI
Solicitation Number:
N/A
Small Business Information
PERSCITUS BIOSCIENCES, LLC
PERSCITUS BIOSCIENCES, LLC 3587 ANDERSON ST, STE 104 MADISON, WI 53704
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2010
Title: A novel compound to selectively protect normal tissues from chemotherapy
Agency: HHS
Contract: 1R43CA137933-01A2
Award Amount: $147,830.00
 

Abstract:

DESCRIPTION (provided by applicant): The successful treatment of human cancer depends on the ability to find treatments that kill tumor cells without impacting normal tissue significantly. An alternative approach is to selectively protect normal tissue fro m the toxic effects of chemotherapy while leaving the tumor cells vulnerable. Perscitus Biosciences, LLC has successfully synthesized a compound that we hypothesize will increase the protective molecule glutathione in normal tissue but not tumor tissue. Gl utathione is known to protect against reactive oxygen species including those generated during the treatment of cancer with chemotherapy. In this project, we will examine the ability of the compound to selectively increase glutathione levels in normal tiss ue - and not tumor tissue - to protect against chemotherapy- induced toxicity. Analytic methods will be developed in conjunction with the Ohio State University Comprehensive Cancer Center Pharmacoanalytic Laboratory to allow us to measure the different met abolic steps that this compound must undergo to generate glutathione. If successful, this compound could significantly decrease much of the toxicity seen with common chemotherapy treatments of cancer. Importantly, protection of the normal tissue will allow escalation of the doses used in cancer treatment, potentially improving the ability to treat cancer effectively. PUBLIC HEALTH RELEVANCE: Over 500,000 people die from cancer in the U.S. each year. To improve the treatment of cancer, treatment regi mens are needed with improved tolerability and effectiveness. The compound presented in this project has the potential to both decrease the side effects associated with cancer treatment as well as improve the anti-cancer effect.

Principal Investigator:

Kristine K. Hahn
6083109568
KHAHN@PERSCITUSBIO.COM

Business Contact:


scthomas@tds.net
Small Business Information at Submission:

PERSCITUS BIOSCIENCES, LLC
PERSCITUS BIOSCIENCES, LLC 3587 ANDERSON ST, STE 104 MADISON, WI 53704

EIN/Tax ID: 171101785
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No